Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4262
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYilmaz, A.U.-
dc.contributor.authorOztop, I.-
dc.contributor.authorCiloglu, A.-
dc.contributor.authorOkan, T.-
dc.contributor.authorTekin, U.-
dc.contributor.authorYaren, Arzu.-
dc.contributor.authorSomali, I.-
dc.date.accessioned2019-08-16T11:33:04Z-
dc.date.available2019-08-16T11:33:04Z-
dc.date.issued2007-
dc.identifier.issn1368-5031-
dc.identifier.urihttps://hdl.handle.net/11499/4262-
dc.identifier.urihttps://doi.org/10.1111/j.1742-1241.2007.01323.x-
dc.description.abstractThe cardiac toxicity of LV5FU2 (de Gramont) regimen which is a widely used chemotherapy regimen in gastrointestinal system cancers is not well defined. We aimed to evaluate the impact of this regimen on cardiac rhythm. Two Holter ECG recordings were obtained in all patients with gastrointestinal system cancers treated with LV5FU2 regimen as first-line chemotherapy (one before and the second during the first 24 h of chemotherapy). Records were reviewed for the heart rate, rhythm, atrial premature complexes (APC), ventricular premature complexes (VPC), grades according to Lown-Wolf grading system and ST segment changes. Holter ECG recordings were evaluated in 27 patients. In the baseline evaluation, neither clinical symptom nor ST segment changes were observed. During the treatment period, chest pain was observed in two patients without any cardiac enzyme and ST segment changes. Moreover, a decrease in mean heart rate, and an increase in the number and complexity of premature complexes secondary to treatment were observed. The mean heart rate, APC per hour and VPC per hour (±SD) before vs. during treatment were, respectively, 93.1 ± 16.4 vs. 81.6 ± 12.7 (p = 0.001), 18.9 ± 54.0 vs. 45.3 ± 53.8 vs. (p = 0.049) and 12.7 ± 29.6 vs. 38.1 ± 42.1 (p = 0.002). LV5FU2 regimen leads to a decrease in mean heart rate and a significant increase in APC and VPC which may lead to serious arrhythmias. These effects must be better understood for a safer administration of this useful and widely used drug regimen. © 2007 The Authors.en_US
dc.language.isoenen_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantihypertensive agenten_US
dc.subjectantineoplastic agenten_US
dc.subjectfluorouracilen_US
dc.subjectfolinic aciden_US
dc.subjectheart enzymeen_US
dc.subjectoral antidiabetic agenten_US
dc.subjectadjuvant therapyen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectambulatory monitoringen_US
dc.subjectarticleen_US
dc.subjectcancer adjuvant therapyen_US
dc.subjectcancer combination chemotherapyen_US
dc.subjectcardiotoxicityen_US
dc.subjectclinical articleen_US
dc.subjectclinical observationen_US
dc.subjectclinical trialen_US
dc.subjectcontinuous infusionen_US
dc.subjectdiabetes mellitusen_US
dc.subjectdigestive system canceren_US
dc.subjectdrug safetyen_US
dc.subjectesophagus canceren_US
dc.subjectfemaleen_US
dc.subjectheart rateen_US
dc.subjectheart rhythmen_US
dc.subjectheart ventricle extrasystoleen_US
dc.subjectHolter monitoringen_US
dc.subjecthumanen_US
dc.subjecthypertensionen_US
dc.subjectliver canceren_US
dc.subjectloading drug doseen_US
dc.subjectmaleen_US
dc.subjectmedical record reviewen_US
dc.subjectmetastasisen_US
dc.subjectmultiple cycle treatmenten_US
dc.subjectpatient assessmenten_US
dc.subjectpriority journalen_US
dc.subjectside effecten_US
dc.subjectST segmenten_US
dc.subjectstomach canceren_US
dc.subjectsupraventricular premature beaten_US
dc.subjectsymptomen_US
dc.subjectthorax painen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAntimetabolites, Antineoplasticen_US
dc.subjectCardiac Complexes, Prematureen_US
dc.subjectElectrocardiography, Ambulatoryen_US
dc.subjectFemaleen_US
dc.subjectFluorouracilen_US
dc.subjectGastrointestinal Neoplasmsen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectProspective Studiesen_US
dc.title5-Fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoringen_US
dc.typeArticleen_US
dc.identifier.volume61en_US
dc.identifier.issue5en_US
dc.identifier.startpage795-
dc.identifier.startpage795en_US
dc.identifier.endpage801en_US
dc.identifier.doi10.1111/j.1742-1241.2007.01323.x-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid17493091en_US
dc.identifier.scopus2-s2.0-34247113188en_US
dc.identifier.wosWOS:000245608700016en_US
dc.identifier.scopusqualityQ2-
dc.ownerPamukkale University-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

37
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

34
checked on Dec 20, 2024

Page view(s)

60
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.